The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

Adding adjuvant pertuzumab to standard adjuvant chemotherapy and trastuzumab improved overall survival at 11 years of follow-up in patients with early human epidermal growth factor receptor 2 ...

Read more about Cryptonews As 2025 unfolds, the bedrock consensus mechanisms powering Bitcoin and Ethereum—proof-of-work (PoW) and proof-of-stake (PoS)—are under fire after hacks and halving-driven ...

"This preliminary work opens exciting avenues for future research to clarify the underlying mechanisms and to develop new improved therapies focusing on increasing energy expenditure for long-term ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast cancer, according to new results from a long-term study of the drug. The ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and chemotherapy reduces the risk of death by 17% in HER2-positive early breast cancer.

(RTTNews) - CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors. CytoDyn analyzed ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta ® (pertuzumab), Herceptin ® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post ...

The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten-year data ...